Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
367 people get TRGT articles and Market Currents by email alert.
Get email alerts on TRGT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 29, 2013)
-
-
Business Wire (Apr 22, 2013)
-
Business Wire (Apr 18, 2013)
-
-
Insiders Are Buying These 4 Cash Rich CompaniesKapitall • Sun, Apr 7
-
Business Wire (Mar 18, 2013)
-
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 26, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Feb 4, 2013)
-
BioLine Is Approaching Its Moment Of TruthBioassociate Consulting • Mon, Dec 3, 2012 -
Business Wire (Nov 27, 2012)
-
Business Wire (Nov 15, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Targacept's Depressing Plunge As Antidepressant FailsDerek Lowe • Wed, Nov 9, 2011 -
Targacept: Ready to Take OffJason Chew • Mon, Jun 21, 2010 -
Expect Targacept to Move HigherDan Rosenblum • Wed, Oct 21, 2009 -
Tiny Targacept Experiences Unusual Volume SurgeH.S. Ayoub • Wed, Apr 18, 2007
-
-
-
Insiders Are Buying These 4 Cash Rich CompaniesKapitall • Sun, Apr 7
-
-
BioLine Is Approaching Its Moment Of TruthBioassociate Consulting • Mon, Dec 3, 2012
-
-
-
-
-
-
-
-
-
Tracking Seth Klarman's Baupost Group Holdings: Q1 2012 UpdateJohn Vincent • Mon, May 14, 2012 -
-
-
-
-
Tuesday Options RecapFrederic Ruffy • Tue, Mar 20, 2012 -
-
Targacept Q4 2009 Earnings Call TranscriptFri, Feb 12, 2010
-
Targacept, Inc. Q3 2009 Earnings Call TranscriptThu, Nov 5, 2009
-
Targacept, Inc. Q2 2009 Earnings Call TranscriptWed, Aug 5, 2009
-
Targacept, Inc. Q4 2008 Earnings Call TranscriptThu, Feb 12, 2009
-
Targacept, Inc. Q3 2008 Earnings Call TranscriptThu, Nov 20, 2008
-
Targacept, Inc Q2 2008 Earnings Call TranscriptTue, Aug 5, 2008
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 22, 2013)
-
Business Wire (Apr 18, 2013)
-
Business Wire (Mar 18, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 26, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Feb 4, 2013)
-
Business Wire (Nov 27, 2012)
-
Business Wire (Nov 15, 2012)
-
Business Wire (Nov 6, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Oct 11, 2012)
-
Business Wire (Oct 8, 2012)
-
at MarketWatch.com (Sep 18, 2012)
-
Business Wire (Sep 17, 2012)
-
Business Wire (Sep 5, 2012)
TRGT vs. ETF Alternatives
Company Description
We are a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics™, a new class of drugs for the treatment of diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Tuesday, September 18, 2012, 9:10 AM
Premarket gainers: VELT +12%. DOLE +7%. TRGT +7%. ROSG +6%.
Losers: AMD -9%. CLWR -6%. 1 Comment [On the Move] - Tuesday, September 18, 2012, 8:59 AM Shares of Targacept (TRGT) trade 6.7% higher premarket a day after a Phase 2 trial of the firm's TC-5619 drug candidate rattled investors. Adam Feuerstein says the company's promising pipeline helps to keep the name interesting to institutional investors. Comment! [On the Move, Healthcare]
- Monday, September 17, 2012, 12:04 PM Shares of Targacept (TRGT -11%) take a hit today after the drug developer says that Phase II trials of TC-5619 - for the treatment of inattentive-predominant attention deficit/hyperactivity disorder - did not meet their primary endpoint. Quixotically, the trial results showed patients on a placebo consistently improved more than patients on TC-5619. Comment! [Healthcare, On the Move]
-
Tuesday, April 10, 2012, 9:15 AM
Premarket gainers: XRIT +39%. NBG +27%. SVU +16%. YPF +8%. AKRX +8%. LGF +3%.
Losers: VPHM -20%. TRGT -9%. SNE -8%. STD -4%. STM -4%. AU -3%. TS -3%. MT -3%. 1 Comment [On the Move] - Tuesday, April 10, 2012, 9:14 AM Targacept (TRGT) -10.3% premarket after announcing revised top-line results from its exploratory Phase 2 study of TC-6987 in asthma show it no longer achieves protocol-defined success criteria on the primary endpoint of Forced Expiratory Volume. Comment! [Healthcare, On the Move]
- Tuesday, March 27, 2012, 8:23 AM Shares of Targacept (TRGT) fall 5.0% in premarket trading after the company announces that it will discontinue a clinical trial of its TC-5214 treatment for depression and releases disappointing results from a study of its TC-6987 diabetes treatment candidate. Comment! [On the Move, Healthcare]
-
Tuesday, March 20, 2012, 9:05 AM
Premarket gainers: FMCN +8%. ZLCS +7%. WMB +4%. KORS +4%. TIF +4%.
Losers: TRGT -16%. JASO -9%. FRO -6%. RGP -5%. ADBE -4%. GEN -4%. ALV -4%. RIO -4%. IRE -3%. MT -3%. BHP -3%. CLF -3%. AKS -3%. SDRL -3%. S -3%. ING -3%. Comment! [On the Move] - Tuesday, March 20, 2012, 8:50 AM Targacept (TRGT) -15% premarket after the antidepressant it was testing with AstraZeneca (AZN) failed in its last two late-stage studies, ending plans to seek regulatory approval. The two companies said on Dec. 20 the drug hadn’t met its target in a late-stage trial, and the latest failure was the final of four trials on the therapy. Comment! [Healthcare, On the Move]
-
Thursday, January 5, 2012, 9:14 AM
Premarket gainers: SODA +9%. PSUN +8%. STX +7%. ITMN +6%. TRGT +6%. SIRI +4%.
Losers: BKS -29%. AEO -17%. PLCE -13%. TSO -8%. DB -7%. STD -6%. JCP -6%. HPG -4%. VLO -4%. EK -4%. KSS -4%. UBS -4%. TGT -4%. PCS -3%. VOD -3%. LLY -3%. E -3%. CRH -3%. ALU -3%. 2 Comments [On the Move] - Tuesday, December 20, 2011, 12:47 PM Targacept (TRGT -32.1%) catches the eye of analysts a bit late after the firm bombs with Phase III clinical results for its antidepressant drug-candidate TC-5214. Leerink Swann downgrades shares to Market Perform from Outperform, while Global Hunter takes its rating down to Neutral from Accumulate. Comment! [On the Move, Healthcare]
-
Tuesday, December 20, 2011, 9:05 AM
Premarket gainers: CSIQ +27%. PGNX +26%. AIS +17%. SLXP +11%. S +7%. CLWR +7%. JEF +6%. ALU +6%. NOK +5%. DB +5%. RIO +5%. MT +4%. STD +4%. BBVA +4%. STM +4%. VHC +4%. GSS +4%. ANR +4%. MS +4%. ERIC +4%. BHP +3%. ZMH +3%. VALE +3%. ITUB +3%. SNE +3%. C +3%. VE +3%. X +3%. MU +3%. HAL +3%. SI +3%.
Losers: TRGT -22%. RHT -8%. GFA -4%. Comment! [On the Move] - Tuesday, December 20, 2011, 7:51 AM Shares of AstraZeneca (AZN) fall 3.3% in London trading as news that partner Targacept's (TRGT) depression treatment failed to meet a goal adds to a string of misfires with its development pipeline. Analysts at Barclays Capital say that the buildup failures will prompt management to "reassess the likely return on investment from additional R&D investment and cut costs further." Comment! [On the Move, Global & FX, Healthcare]
- Tuesday, December 20, 2011, 7:43 AM Shares of Targacept (TRGT) slide 26% after the firm releases top-line results from its second Phase 3 study of its antidepressant therapy TC-5214 that fails to meet its primary goal. Comment! [On the Move, Healthcare]
-
Wednesday, November 9, 2011, 9:00 AM
Premarket gainers: YONG +13%. SODA +13%. KITD +10%. CTEL +5%. PANL +5%.
Losers: ROVI -25%. MFB -21%. STEC -18%. HDY -15%. ING -13%. ADBE -10%. RBS -9%. FIO -9%. ALU -8%. HBC -8%. DB -8%. NCT -8%. BCS -8%. VE -8%. MT -8%. LYG -7%. GM -7%. STP -7%. BZH -7%. ERIC -7%. RDN -6%. TRGT -6%. RL -6%. UBS -6%. RCL -6%. G -5%. ASML -5%. FTE -5%. GRPN -5%. SI -5%. ARMH -5%. SI -5%. MS -5%. NBG -5%. TOT -5%. NOK -5%. RCH -5%. AKS -4%. TEF -4%. Comment! [On the Move] -
Tuesday, November 8, 2011, 9:05 AM
Premarket gainers: MSSR +28%. DYN +20%. YPF +7%. BCRX +9%. NBG +6%. ING +6%. DRYS +6%. SIG +6%. FRO +6%. LYG +5%. RAX +5%. RENN +5%. GTAT +4%. PLCM +4%. NVO +3%. ASML +3%. ATVI +3%. DNDN +3%. AMRN +3%. HFC +3%. JEF +3%. EK +3%.
Losers: TRGT -55%. AMLN -9%. JRCC -7%. ALLT -7%. FOSL -7%. LGCY -5%. TGI -5%. PXD -4%. ETP -4%. INHX -3%. ALU -3%. URBN -3%. AZN -3%. Comment! [On the Move] - Tuesday, November 8, 2011, 7:08 AM Targacept (TRGT) and AstraZeneca (AZN) announce their experimental depression pill failed to show any improvement for patients in a clinical trial. The firms are studying TC-5214 as a potential additional therapy for patients no longer responding to other antidepressants. Premarket: TRGT -50.3%, AZN -3.3%. Comment! [On the Move, Healthcare]
-
- View all 1 replies
-
vireoman: So the spraying of Afrezza into one's nose evidently doesn't contribute to global warming?
-
- View all 0 replies
-
- View all 0 replies
-
Bryce Istvan
TRGT tanking after decision not to file for approval of -5214. Why was this a surprise? http://seekingalpha.com/a/6r18 - View all 0 replies
-
Michael Bryant
Targacept (TRGT) looks like a gamble. Maybe the fund manager sees something. http://yhoo.it/ABagPU;c= http://bit.ly/wWcpvX - View all 0 replies
-
Jacob Wolinsky
Seth Klarman Purchases 18% Stake in Targacept | ValueWalk.com http://bit.ly/xCsfRo $TRGT - View all 0 replies
-
Jacob Wolinsky
Exclusive: Seth #Klarman's Secret Holdings @ ValueWalk.com http://bit.ly/umoGXV #debt #shorts $TRGT $BP $NWSA $CSE $HP $PDLI $MSFT $ERO - View all 0 replies
-
- View all 3 replies
-
ron49er: I don't know, but the stock hit $7 last week so I guess the answer to my question was yes.
-
-
- View all 14 replies
-
Michael Kudrna: it's all about timeframe. you can sit on a bad stock but if you give it 10 years, somewhere in that timeframe you can make good money -
John Rayhall: Or ala Enron or MF global maybe you won't make it back. I hear what you're saying though.
-
- View all 2 replies
-
-
Demi9OD: MK wasn't pumping really, just riding it up. Unfortunate trial results.
LATEST REPLIES
-
- View all 1 replies
-
vireoman: So the spraying of Afrezza into one's nose evidently doesn't contribute to global warming?
-
- View all 3 replies
-
ron49er: I don't know, but the stock hit $7 last week so I guess the answer to my question was yes.
-
-
- View all 14 replies
-
Michael Kudrna: it's all about timeframe. you can sit on a bad stock but if you give it 10 years, somewhere in that timeframe you can make good money
-
John Rayhall: Or ala Enron or MF global maybe you won't make it back. I hear what you're saying though.
-
- View all 2 replies
-
-
Demi9OD: MK wasn't pumping really, just riding it up. Unfortunate trial results.
-
Michael Kudrna
Disappointing data results for $TRGT. Only holding profits, so will close out my reduced profits this morning $$ - View all 11 replies
-
-
-
Michael Kudrna
A Strong Season For Trading (w/ Economic Calendar, Stock Radar & Jobs Report) $SPY $IWM $TRGT $VIVO $CSIQ $$ http://bit.ly/vIYOp6/ - View all 2 replies
-
-
Michael Kudrna: Topsi, I sent you a reply on SeekingAlpha email system. Hope it helps.
-
- View all 2 replies
-
-
Michael Kudrna: I'm a technical/momentum trader...many times breakouts happen without news. However this is due to high expectations for phase 3 data
-
Michael Kudrna
Reducing $TRGT in the green as rumors swirl that all the option activity today is because we are about to receive phase 3 data $$ - View all 2 replies
-
Native Texan: Are you still holding yoru short position or did you get out at 1233? -
Michael Kudrna: got stopped out as I was typing that StockTalk actually. Don't want to play with fire and hold if we stay above 1233